Cardiovascular security as selection criteria for nonsteroidal anti-inflammatory drugs in the treatment of pain syndromes

Cover Page

Cite item

Full Text

Abstract

The problem of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with the development of complications of the cardiovascular system and gastrointestinal tract. The review presents the results of clinical and epidemiological studies on the efficacy and safety of naproxen, demonstrating the lowest among all NSAIDs the risk of developing complications of the cardiovascular system.

About the authors

V. A Shirokov

Clinic of neurology; Yekaterinburg Medical Research Center for Prophylaxis and Health Protection of Industrial Workers of Rospotrebnadzor

Email: vashirokov@gmail.com
д-р мед. наук, проф., рук. НПО «Клиника неврологии», ФБУН Екатеринбургский медицинский научный центр ПОЗРПП 620014, Russian Federation, Ekaterinburg, ul. Moskovskaia, d. 12

References

  1. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике (клинические рекомендации). Совр. ревматология. 2015; 1: 361.
  2. Насонов Е.Л. Вступительное слово. РМЖ. 2015; 7: 361.
  3. Каратеев А.Е. Модификация традиционных НПВП как метод повышения их безопасности и удобства применения. РМЖ. 2015: 7: 392-8.
  4. Широков В.А. Выбор нестероидных противовоспалительных препаратов в лечении болевого синдрома с позиции кардиоваскулярной безопасности. РМЖ. 2015; 12: 716-9.
  5. Loo C, Tan H, Teh H, Raymond A. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 2007; 48 (9): 834-9.
  6. Strand V, Simon L.S, Dougados M et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol 2011; 38 (12): 2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.
  7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
  8. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta - analysis. Lancet 2004; 364: 2021-29.
  9. Kimmel S.E, Berlin J.A, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157-64.
  10. Bresalier R.S, Sandier R.S, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
  11. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009.
  12. Garcia Rodriguez L.A, Varas C, Patrono C. Differential effects of aspirin and non - aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiol 2000; 11: 382-7.
  13. Garcia Rodriguez L, Varas-Lorenzo C, Maguire A et al. Non - steroidal anti - inflammatory drugs and the risk of myocardial infarction in general population. Circulation 2004; 109: 3000-6.
  14. Watson D.J, Rhodes T, Cai B, Guess H.A. Lower risk of thromboembolic cardiovascular eventswith naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105-11.
  15. Mac Donald T, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
  16. Ray W.A, Stein C.M, Hall K et al. Non - steroidal anti - inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-23.
  17. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of nonsteroidal anti - inflammatory drugs: network meta - analysis. BMJ 2011; Jan 11: 342: c7086. doi: 10.1136/bmj.c7086.
  18. Mc Gettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296: 1633-44.
  19. Wong D, Wang М, Cheng Y, Fitzgerald G.A. Cardiovascular hazard and non - stertoidal anti - inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204-10.
  20. Chan C.C, Reid C.M, Aw T.J et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta - analysis. J Hypertens 2009; 27 (12): 2332-41. doi: 10.1097/HJH.0b013e3283310dc9
  21. Solomon D, Glynn R, Levin R, Avarn J. Nonsteroidal anti - inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-4.
  22. Vascular and upper gastrointestinal effects of non - steroidal anti - inflammatory drugs: meta - analyses of individual participant data from randomised trials Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Lancet 2013; 382: 769-79.
  23. Sharon Hertz. Cайт FDA.
  24. Singh G, Graham D, Wang H et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some nonselective nonsteroidal anti - inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61 (OP0024 abst.).
  25. Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti - inflammatory drugs meta - analysis of observational studie. Pharmacoepidemiol Drug Saf 2013; 22: 559-70. doi: 10.1002/pds Published online 25 April 2013 in Wiley OnlineLibrary
  26. Инструкция по медицинскому применению препарата Налгезин.
  27. Инструкция по медицинскому применению препарата Налгезин форте.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies